ExcelMale
Menu
Home
What's new
Latest activity
Forums
New posts
Search forums
What's new
New posts
Latest activity
Videos
Lab Tests
Doctor Finder
Buy Books
About Us
Men’s Health Coaching
Log in
Register
What's new
Search
Search
Search titles only
By:
New posts
Search forums
Menu
Log in
Register
Navigation
Install the app
Install
More options
Contact us
Close Menu
Forums
Testosterone Replacement, Low T, HCG, & Beyond
Testosterone Side Effect Management
CYP3A interactions with TRT Meds
JavaScript is disabled. For a better experience, please enable JavaScript in your browser before proceeding.
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an
alternative browser
.
Reply to thread
Message
<blockquote data-quote="Blackhawk" data-source="post: 171699" data-attributes="member: 16042"><p>Thanks Dr Saya, LOL! I wish the message had reached you directly, but glad to know it hasn't, I wouldn;t have known otherwise. Message sent to your email this morning, perhaps blocked on your end due to attachment or included link? Should I re-send?</p><p></p><p>I believe the doctor said Venetoclax in an inducer, but this document says substrate, Page 5 <a href="http://www.bccancer.bc.ca/drug-database-site/Drug%20Index/Venetoclax_monograph.pdf" target="_blank">http://www.bccancer.bc.ca/drug-database-site/Drug Index/Venetoclax_monograph.pdf</a></p><p></p><p>There are some contraindications for inhibitors, and strong inducers. I think that the metabolic clearance of T and anastrozole are not at issue unless they are inhibitors or strong inducers. Sounds like you are concerned with how the Venetoclax affect the hormone drugs and the onc is concerned with the effect of the hormone drugs on the venetoclax! I reckon both are on the table!</p><p></p><p><a href="https://www.rxabbvie.com/pdf/venclexta.pdf" target="_blank">https://www.rxabbvie.com/pdf/venclexta.pdf</a></p><p>Dosage modifications for CYP3A: section 2.4 PDF page 9</p><p>Contraindications CYP3A: Section 4 PDF page 11</p><p>CYP3A inhibitors and tumor Lysis: Section 5.1 paragraph 5 PDF page 11</p><p>Drug interactions: Section 7.1 PDF page 26</p><p>Metabolism: PDF page 31</p><p>Other in vitro study info: PDF page 32</p><p></p><p></p><p>EDIT: Also: <a href="https://www.researchgate.net/publication/312081962_Quantitative_Prediction_of_the_Effect_of_CYP3A_Inhibitors_and_Inducers_on_Venetoclax_Pharmacokinetics_Using_a_Physiologically_Based_Pharmacokinetic_Model_Journal_of_Clinical_Pharmacology" target="_blank">Quantitative Prediction of the Effect of CYP3A Inhibitors and Inducers on Venetoclax Pharmacokinetics Using a Physiologically Based Pharmacokinetic Model: Journal of Clinical Pharmacology | Request PDF</a></p></blockquote><p></p>
[QUOTE="Blackhawk, post: 171699, member: 16042"] Thanks Dr Saya, LOL! I wish the message had reached you directly, but glad to know it hasn't, I wouldn;t have known otherwise. Message sent to your email this morning, perhaps blocked on your end due to attachment or included link? Should I re-send? I believe the doctor said Venetoclax in an inducer, but this document says substrate, Page 5 [URL]http://www.bccancer.bc.ca/drug-database-site/Drug%20Index/Venetoclax_monograph.pdf[/URL] There are some contraindications for inhibitors, and strong inducers. I think that the metabolic clearance of T and anastrozole are not at issue unless they are inhibitors or strong inducers. Sounds like you are concerned with how the Venetoclax affect the hormone drugs and the onc is concerned with the effect of the hormone drugs on the venetoclax! I reckon both are on the table! [URL]https://www.rxabbvie.com/pdf/venclexta.pdf[/URL] Dosage modifications for CYP3A: section 2.4 PDF page 9 Contraindications CYP3A: Section 4 PDF page 11 CYP3A inhibitors and tumor Lysis: Section 5.1 paragraph 5 PDF page 11 Drug interactions: Section 7.1 PDF page 26 Metabolism: PDF page 31 Other in vitro study info: PDF page 32 EDIT: Also: [URL='https://www.researchgate.net/publication/312081962_Quantitative_Prediction_of_the_Effect_of_CYP3A_Inhibitors_and_Inducers_on_Venetoclax_Pharmacokinetics_Using_a_Physiologically_Based_Pharmacokinetic_Model_Journal_of_Clinical_Pharmacology']Quantitative Prediction of the Effect of CYP3A Inhibitors and Inducers on Venetoclax Pharmacokinetics Using a Physiologically Based Pharmacokinetic Model: Journal of Clinical Pharmacology | Request PDF[/URL] [/QUOTE]
Insert quotes…
Verification
Post reply
Share this page
Facebook
Twitter
Reddit
Pinterest
Tumblr
WhatsApp
Email
Share
Link
Sponsors
Forums
Testosterone Replacement, Low T, HCG, & Beyond
Testosterone Side Effect Management
CYP3A interactions with TRT Meds
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.
Accept
Learn more…
Top